Study to Assess Safety and Tolerability of AZD2171 After Multiple Doses in Patients With Advanced Prostate Cancer

Inclusion Criteria: * Men, 18yrs and older * Histological or cytological confirmation of prostate adenocarcinoma (symptomatic or asymptomatic) * Prior hormonal therapy, and/or no more than 1 prior chemotherapy regimen (including estramustine and/or corticosteroids) for treatment of prostate adenocarcinoma Exclusion Criteria: * Prior radiotherapy to bone metastases within 4 weeks prior to screening * any unresolved chronic toxicity greater than CTCAE grade 2 from previous anticancer therapy * Brain metastases or spinal cord compression, unless treated at least 4 weeks before entry, and stable with steroid treatment for 1 week.